Sign in
Taking people in United StatesPhase 2

Fisetin for walking difficulty in people with peripheral artery disease

Tests fisetin against placebo for walking and aging cells in peripheral artery disease.

Key facts

Who runs it
Northwestern University
Where
Chicago, United StatesSee the site
Trial code
Registry title
Fisetin to Reduce Senescence and Mobility Impairment in PAD
Status
Recruiting
Phase
Phase 2
People taking part
34 people, planned
Started
30 Sept 2024
Expected to end
Jun 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Fisetin
  • Placebo
Record updated
15 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 50 and older with peripheral artery disease (PAD), a narrowing of leg arteries that limits walking. It tests whether fisetin improves walking compared with placebo.

Age
50 years and older
Sex
All sexes. Women can join only after menopause (no period in the past 12 months).
Disease stage
PAD shown by an ankle brachial index (ABI) of 0.90 or less, or vascular lab or angiography evidence (at least 70% narrowing of a leg artery), or an ABI above 0.90 and up to 1.00 with a 20% or greater drop after a heel-rise test. Six-minute walk distance must be between 500 feet and 1600 feet.
Earlier treatment
No fisetin in the previous three months. No supervised treadmill exercise program in the previous three months. No major surgery, heart or leg artery procedure in the previous three months.

Main reasons for not taking part

  • Leg amputation, severe loss of blood flow to the leg (critical limb ischemia), or a foot ulcer on the bottom of the foot
  • Using a wheelchair or walker, or walking limited by something other than PAD
  • Major illness such as lung disease needing oxygen, Parkinson's disease, or cancer treated in the past two years
  • Living with HIV, or active hepatitis B or C without a low viral load
  • Severe kidney weakness (eGFR less than 25 ml/min/1.73 m2), HemoglobinA1C above 10, or BMI above 43

The registry criteria, word for word

Show all 31 criteriaShow less

Who can take part

  • First, all participants will be age 50 and older. Second, all participants will have PAD. PAD will be defined as:
  • An ankle brachial index (ABI) less than or equal to 0.90 at baseline
  • Vascular lab evidence of PAD (such as a toe brachial pressure less than or equal to 0.70 or an ankle brachial index less than or equal to 0.90), or angiographic evidence of PAD defined as at least 70% stenosis of an artery supplying the lower extremities
  • An ABI of greater than 0.90 and less than or equal to 1.00 who experience a 20% or greater drop in ABI in either leg after the heel-rise test will also be included

Who cannot take part

  • Planned major surgery, coronary or leg revascularization during the next five months
  • Major surgery, coronary or leg revascularization or major cardiovascular event in the previous three months
  • Major medical illness including lung disease requiring oxygen, Parkinson's disease, a life-threatening illness with life expectancy less than six months, or cancer requiring treatment in the previous two years. [NOTE: potential participants may still qualify if they have had treatment for an early stage cancer in the past two years and the prognosis is excellent. Participants who require oxygen only at night may still qualify.]
  • Currently taking fisetin or has taken fisetin in previous three months
  • Current participation in or completion of a clinical trial intervention in the previous three months. [NOTE: after completing a stem cell or gene therapy intervention, participants will become eligible after the final study follow-up visit of the stem cell or gene therapy study so long as at least six months have passed since the final intervention administration. After completing a clinical trial (other than stem cell or gene therapy), participants will be eligible after the final study intervention as long as at least three months have passed since the final intervention of the trial.]
  • Participation in a supervised treadmill exercise program in previous three months
  • People taking warfarin and other sensitive substrates of CYP2C9, CYP2C19, or CYP1A2 that have a narrow therapeutic window will be excluded, unless the drug can be held for at least two days prior to the first day of each study drug administration and can continue to be held for ten hours after the second dose of study drug administration for each of the two days of study drug dosing
  • Current foot ulcer on bottom of foot
  • Failure to successfully complete the study run-in
  • Allergy to fisetin
  • Visual impairment that limits walking ability
  • HemoglobinA1C great than 10 as a marker of poor diabetes control
  • People who are Human Immunodeficiency Virus positive (HIV+) and people with active hepatitis B or active hepatitis C infections who do not have a low viral load
  • People with a bilirubin above 2.2 mg/dl, with serum aspartate transaminase (AST) or alanine aminotransferase (ALT) more than four times the upper limit of normal
  • Hemoglobin less than 7.0 g/dl, white blood count less than 2,000/mm3, white blood count greater than 20,000/mm3, platelet count less than 40,000/uL
  • Estimated glomerular filtration rate (eGFR) less than 25 ml/min/1.73 m2
  • In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant. In some instances, patients whose medications or laboratory data meet exclusion criteria may participate at the Principal Investigator's discretion
  • Above- or below-knee amputation
  • Critical limb ischemia defined as an ABI less than 0.40 with signs or symptoms of critical limb ischemia
  • Wheelchair confinement or requiring a walker to ambulate
  • Walking is limited by a symptom other than PAD
  • Mini-Mental Status Examination (MMSE) score less than 23
  • Non-English speaking
  • Six-minute walk distance of less than 500 feet or greater than1600 feet
  • Participants may be excluded if they are unwilling to undergo a fat biopsy. However, if investigators find recruitment significantly slows due to this exclusion, participants may still be able to participate in the trial if they refuse the fat biopsy
  • Women who are not menopausal will be excluded. Menopause is defined as absence of a menstrual period in the past 12 months
  • Body mass index (BMI) great than 43

Where in United States

  • Northwestern University Feinberg School of MedicineChicago, United StatesContact: Kathryn J DomanchukTaking people

About the trial

What the trial wants to find out

The investigators propose a pilot randomized trial to gather preliminary data to test the hypothesis that Fisetin will reduce abundance of senescent cells in blood, skeletal muscle, and both subcutaneous and inter muscular adipose tissue and improve 6-minute walk distance in 34 people with peripheral artery disease (PAD). the investigators will determine whether greater declines in abundance of cells with senescent markers are associated with greater improvement in 6-minute walk distance in people with peripheral artery disease. In exploratory analyses, the investigators will assess whether Fisetin reduces interleukin-6 (IL-6) and novel senescent markers in adipose tissue, muscle, and/or blood.

The 2 groups in the trial

  • FisetinTreatment being tested

    Sharp Clinical Services will provide fisetin (100 mg capsules). Randomized participants will receive fisetin 20 mgs/kg once daily for two days, followed by 12 days without therapy. Fisetin will be dosed in 100 mg tablets. Dosing will be rounded to the nearest 100 mg. For example, a 73 kg participant with a dose of 1,460 mg (i.e.73 kg x 20 mg) receives 1,500 mgs daily (i.e. 15 x 100 mg capsules) for two days every 14 days.

  • PlaceboPlacebo, for comparison

    Sharp Clinical Services will provide placebo (100 mg capsules). Randomized participants will receive placebo 20 mgs/kg once daily for two days, followed by 12 days without therapy. Placebo will be dosed in 100 mg tablets. Dosing will be rounded to the nearest 100 mg. For example, a 73 kg participant with a dose of 1,460 mg (i.e.73 kg x 20 mg) receives 1,500 mgs daily (i.e. 15 x 100 mg capsules) for two days every 14 days.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Fisetin to Reduce Senescence and Mobility Impairment in Peripheral Artery Disease: the FIRST Pilot Randomized Trial
Plain-language title
Fisetin for walking difficulty in people with peripheral artery diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
15 April 2026